BioCryst Pharmaceuticals | Należności Handlowe





Należności Handlowe Zmiana Data
Alnylam Pharmaceuticals USD 777.57M 187.2M 2025-12
BioCryst Pharmaceuticals USD 79.07M 6.61M 2024-12
Chugai Pharma JPY 443.11B 89.26B 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
DBV Technologies USD 15.97M 279K 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 4.91B 182M 2025-12
GlaxoSmithKline GBP 7.76B 545M 2025-12
Glaxosmithkline GBP 11.16B 3.46B 2025-09
Incyte USD 1.02B 128.52M 2025-12
Ionis Pharmaceuticals USD 66M 41.39M 2025-12
Karyopharm Therapeutics USD 31.78M 6.82M 2024-09
Neurocrine Biosciences USD 686.8M 41.2M 2025-12
Novavax USD 94.96M 62.81M 2024-09
PTC Therapeutics USD 181.62M 21.45M 2025-12
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 398.23M 2.49M 2025-12
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vertex Pharmaceuticals USD 2.05B 106.4M 2025-12


BioCryst Pharmaceuticals Należności Handlowe - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2026.